- Home
- Editorial
- News
- Practice Guidelines
- Anesthesiology Guidelines
- Cancer Guidelines
- Cardiac Sciences Guidelines
- Critical Care Guidelines
- Dentistry Guidelines
- Dermatology Guidelines
- Diabetes and Endo Guidelines
- Diagnostics Guidelines
- ENT Guidelines
- Featured Practice Guidelines
- Gastroenterology Guidelines
- Geriatrics Guidelines
- Medicine Guidelines
- Nephrology Guidelines
- Neurosciences Guidelines
- Obs and Gynae Guidelines
- Ophthalmology Guidelines
- Orthopaedics Guidelines
- Paediatrics Guidelines
- Psychiatry Guidelines
- Pulmonology Guidelines
- Radiology Guidelines
- Surgery Guidelines
- Urology Guidelines
Probiotics prevent age‐associated bone loss and osteoporosis-Study
Probiotics, dietary supplements with health-promoting bacteria, can be used to prevent bone loss, according to a recent study published in the Journal of Internal Medicine. Among older women who received probiotics, bone loss was halved compared to women who received only a placebo.
Lactobacillus reuteri ATCCPTA 6475 (L. reuteri 6475) has been reported to increase bone mineral density (BMD) in mice but no study has been done to check its efficacy on the human skeleton.
Anna G. Nilsson and his associates conducted a study to investigate if L. reuteri6475 affects bone loss in older women with low BMD.
A total of 90 women were included in the double‐blind, placebo‐controlled study aged from 75 to 80 years old having low BMD. The patients were randomized to orally receive 1010 colony‐forming units of L. reuteri 6475 daily or placebo. The predefined primary end‐point was relative change after 12 months in tibia total volumetric BMD (vBMD).
"When we finished the study after a year, we measured the women's bone loss in their lower legs with a CT scan and compared it with the measurements we made when the study began. The women who received the powder with active bacteria had lost only half as much bone in the skeleton compared with those who received inactive powders," says Anna Nilsson, a chief physician and associate professor at Sahlgrenska Academy, University of Gothenburg. "Another positive outcome from the study was that the treatment was well tolerated and did not produce more side effects than those experienced by women who received the placebo."
The study found that L. reuteri 6475 reduced loss of total vBMD compared to placebo both in the intention‐to‐treat (ITT) analysis and per protocol analysis Similar but smaller effects were observed in the secondary bone variable outcomes but were not statistically significant in the ITT population.
The study concluded that supplementation with L. reuteri 6475 should be further explored as a novel approach to prevent age‐associated bone loss and osteoporosis.
Lactobacillus reuteri 6475 is believed to have multiple health-promoting properties. The bacterium is naturally found in the human gastrointestinal tract.
For more information log on to https://doi.org/10.1111/joim.12805
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd